Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Brachytherapy|November 29, 2008
Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapyPirus Ghadjar, Tamara Keller, Cyrill A Rentsch, et al.
European Urology Focus|November 13, 2018
Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin TherapyCyrill A Rentsch, Laurent Derré, Sarah G Dugas, et al.
Radiation Oncology (London, England)|June 3, 2014
Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancerPirus Ghadjar, Sebastian L Oesch, Cyrill A Rentsch, et al.
Biomedicines|September 28, 2023
Prevalence of Unfavorable Video-Urodynamic Findings and Clinical Implications in Patients with Minimally Conscious State/Unresponsive Wakefulness Syndrome: A Retrospective Descriptive AnalysisFrancois Leboutte, Christian Engesser, Leutrim Zahiti, et al.
Urology|February 12, 2013
Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocolsGeorg Müller, Gernot Bonkat, Malte Rieken, et al.
World Journal of Urology|March 23, 2010
Improved detection of microbial ureteral stent colonisation by sonicationGernot Bonkat, Malte Rieken, Cyrill A Rentsch, et al.
Frontiers in Immunology|October 5, 2017
The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy TestingNatalie E Nieuwenhuizen, Prasad S Kulkarni, Umesh Shaligram, et al.
The Prostate|August 1, 2009
In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissueNatalia Guzmán-Ramírez, Maureen Völler, Antoinette Wetterwald, et al.
International Journal of Cancer|August 18, 2005
Differential expression of TGFbeta-stimulated clone 22 in normal prostate and prostate cancerCyrill A Rentsch, Marco G Cecchini, Ruth Schwaninger, et al.
Endocrine-Related Cancer|April 13, 2013
Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant diseaseTobias Zellweger, Susanne Stürm, Silvia Rey, et al.
Pageof 6